John Ruesch
Corporate Officer/Principal chez ASTRIA THERAPEUTICS, INC.
Profil
John Ruesch is currently the Senior Vice President-Pharmaceutical Sciences at Astria Therapeutics, Inc. Prior to this, he worked as the Vice President-Pharmaceutical Development at Surface Oncology, Inc. Mr. Ruesch completed his undergraduate degree at Valparaiso University and earned an MBA from Kellogg School of Management.
Postes actifs de John Ruesch
| Sociétés | Poste | Début |
|---|---|---|
| ASTRIA THERAPEUTICS, INC. | Corporate Officer/Principal | 17/07/2023 |
Anciens postes connus de John Ruesch
| Sociétés | Poste | Fin |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | - |
Formation de John Ruesch
| Valparaiso University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ASTRIA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |